AstraZeneca: Fasenra fails trial, shares down
(CercleFinance.com) - AstraZeneca's antibody Fasenra failed in a late stage trial in chronic obstructive pulmonary disease patients, slightly hurting the Anglo-Swedish drug-maker's shares on Friday.
The company said the data showed the drug did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD.
Another Phase III randomised double-blind 56-week placebo-controlled trial is ongoing, the firm said, with results expected later this quarter.
AstraZeneca plans to await the results of this second study and a full evaluation of both trials before determining the next steps for Fasenra in COPD.
AstraZeneca shares lost more than 0.7% to trade around 5,216 pence, while the STOXX Europe 600 Optimised Health Care index is down 0.6%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The company said the data showed the drug did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD.
Another Phase III randomised double-blind 56-week placebo-controlled trial is ongoing, the firm said, with results expected later this quarter.
AstraZeneca plans to await the results of this second study and a full evaluation of both trials before determining the next steps for Fasenra in COPD.
AstraZeneca shares lost more than 0.7% to trade around 5,216 pence, while the STOXX Europe 600 Optimised Health Care index is down 0.6%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.